Trosia

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024
CFO, EDT, Acquisition, Total, Injection, Trosia, Investment, Physician, Inflammation, Growth, Eye, Adjustment, Conference, Safety, Alimera Sciences, Depreciation, Patient, Tax, SLR, DME, Macular edema, Video game

ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the fourth quarter and full year 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Key Points: 
  • Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
  • “We are proud to have achieved positive Adjusted EBITDA during the fourth quarter of 2023, while maintaining a consistent net loss compared to the fourth quarter of 2022, despite facing greater interest and amortization expenses following the YUTIQ acquisition.
  • For 2023, international net revenue increased 21% to approximately $24.0 million for 2023, compared to approximately $19.9 million in 2022.
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update

Retrieved on: 
Thursday, February 29, 2024
Physician, Internet access, Alimera Sciences, Trosia, Patient

Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.

Key Points: 
  • Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
  • Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.
  • Those without Internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international).
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, January 2, 2024
Gelesis, Alimera Sciences, Bookkeeping, CFO, Physician, International, Elon University, Growth, Patient, Compensated emancipation, Therapy, Employment, Retina, Trosia

“Elliot joins the Alimera leadership team at an exciting time as we enter 2024 preparing to enhance our growth trajectory and drive improved cash flow,” said Rick Eiswirth, Alimera’s President and CEO.

Key Points: 
  • “Elliot joins the Alimera leadership team at an exciting time as we enter 2024 preparing to enhance our growth trajectory and drive improved cash flow,” said Rick Eiswirth, Alimera’s President and CEO.
  • Most recently he was the Chief Financial Officer with Orgenesis, Inc., a publicly traded global biotech company transforming the processing of cell and gene therapies.
  • At Gelesis, Mr. Maltz advanced from Corporate Controller to Vice President of Finance and then to Chief Financial Officer while leading numerous operational and fundraising initiatives.
  • The Inducement Option is an inducement material to Mr. Maltz entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Alimera Sciences Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, October 26, 2023
Growth, Plaque, EDT, Alimera Sciences, Physician, EBITDA, Injection, Conference, Brachytherapy, Inflammation, Observation, Diabetic retinopathy, CALM, Depreciation, Uveitis, Safety, Fluocinolone acetonide, Cleveland Clinic, Patient, Cryptocurrency, Pharmaceutical industry, Video game, Trosia, Faricimab

Segment

Key Points: 
  • Segment
    ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2023.
  • Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
  • As of September 30, 2023, Alimera had cash and cash equivalents of approximately $8.3 million, compared to $18.8 million on June 30, 2023.
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update

Retrieved on: 
Monday, October 16, 2023
Internet access, Trosia, Alimera Sciences, Physician, Patient

Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.

Key Points: 
  • Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
  • Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.
  • Those without Internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international).
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

Alimera Sciences Appoints Jason Werner as Chief Operating Officer

Retrieved on: 
Tuesday, October 3, 2023
Retina, Tesco international operations, University, Senior, Alimera Sciences, NLRP3, Sun Pharma, Human, Sale, Acquisition, Patient, Physician, Growth, Management, Inflammasome, Trosia

ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer (“COO”), effective October 2, 2023.

Key Points: 
  • ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer (“COO”), effective October 2, 2023.
  • In conjunction with this appointment, Dr. Philip Ashman, previously Alimera’s Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations.
  • Prior to joining Alimera’s management team he has served as the Chief Executive Officer and Board Member of SightStream Biotherapeutics Inc, a biotechnology company focused on developing regenerative medicines in ophthalmics.
  • Mr. Werner previously co-founded and served as Chief Operating Officer of Eyevance Pharmaceuticals through its sale to Santen Pharmaceuticals Ltd.

Alimera Sciences Reports Second Quarter 2023 Results

Retrieved on: 
Thursday, August 10, 2023
Injection, International, DME, Alimera Sciences, Retinal, EBITDA, Trosia, Acquisition, Patient, Physician, Uveitis, Growth, Adjustment, Recurrence, Video game, Retail, Cryptocurrency

Consolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022

Key Points: 
  • Consolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022
    Global End User Demand for ILUVIEN Up 13.5% vs. Second Quarter of 2022
    ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2023.
  • The transaction has provided immediate results, despite planned costs of combining the two products in our infrastructure, contributing to the generation of positive Adjusted EBITDA in the second quarter,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer.
  • In addition, YUTIQ generated an additional 440 units of end user demand in the second quarter from the date of acquisition in late May.
  • As of June 30, 2023, Alimera had cash and cash equivalents of approximately $18.8 million, compared to $13.1 million at March 31, 2023.

Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update

Retrieved on: 
Wednesday, August 2, 2023
Alimera Sciences, Trosia, Patient, Physician, Internet access

Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.

Key Points: 
  • Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
  • Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.
  • All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.
  • A webcast replay of the call will be available approximately one hour after the end of the call through August 24, 2023.

EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Wednesday, August 2, 2023
Maintenance, Employment, Executive, Therapy, Anti-VEGF, SG, Senior, Marketing, Phase II, AMD, Calendar, Clinical trial, Compensated emancipation, Sale, Alimera Sciences, Șaeș, Ophthalmology, Trosia, Eye, Patient, Investment, Webcast, European Society of Gynaecological Oncology, R, Visual acuity, Society, ASRS, Safety, Pharmaceutical industry, Video game

ET –

Key Points: 
  • ET –
    WATERTOWN, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the second quarter ended June 30, 2023 and highlighted recent corporate developments.
  • Review of Results for the Second Quarter Ended June 30, 2023
    For the second quarter ended June 30, 2023, total net revenue was $9.1 million compared to $11.6 million for the quarter ended June 30, 2022.
  • Net product revenue for the second quarter was $5.3 million, compared to net product revenues for the second quarter ended June 30, 2022 of $11.3 million.
  • ET to discuss the results for the second quarter ended June 30, 2023 and recent corporate developments.

EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties

Retrieved on: 
Thursday, May 18, 2023
Drug development, Therapy, SG, DME, Marketing, Calendar, Eye, Diabetic retinopathy, Sale, Alimera Sciences, Patient, Uveitis, Safety, Pharmaceutical industry, Trosia

WATERTOWN, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that it has entered into a definitive agreement for the sale of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences, Inc. (“Alimera”). YUTIQ is a treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. Under the terms of the agreement, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia, where YUTIQ is exclusively licensed to Ocumension Therapeutics (“Ocumension”), and EyePoint will continue to receive royalties from Ocumension for its YUTIQ sales. In exchange for the rights granted to Alimera under the agreement, EyePoint received a $75 million up-front cash payment at closing and will receive an additional $7.5 million in equal quarterly installments in 2024. In addition, commencing in 2025, EyePoint will receive a low to mid double-digit royalty on Alimera’s related U.S. net sales above defined thresholds for the calendar years 2025-2028.

Key Points: 
  • YUTIQ is a treatment for chronic non-infectious uveitis affecting the posterior segment of the eye.
  • In exchange for the rights granted to Alimera under the agreement, EyePoint received a $75 million up-front cash payment at closing and will receive an additional $7.5 million in equal quarterly installments in 2024.
  • In addition, commencing in 2025, EyePoint will receive a low to mid double-digit royalty on Alimera’s related U.S. net sales above defined thresholds for the calendar years 2025-2028.
  • EyePoint and Alimera are committed to ensuring that patients receive uninterrupted access to YUTIQ throughout the transition of YUTIQ sales, marketing and other responsibilities to Alimera.